Mylotarg, fludarabine, cytarabine (Ara-C) and cyclosporine (MFAC) combination regimen in patients with CD33-positive primary resistant or relapsed acute myeloid leukemia (AML).

被引：0
|
作者：
Tsimberidou, AM [1 ]
Estey, E [1 ]
Cortes, J [1 ]
Thomas, D [1 ]
Garcia-Manero, G [1 ]
Faderl, S [1 ]
Verstovesk, S [1 ]
O'Brien, S [1 ]
Kantarjian, H [1 ]
Giles, F [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1317
引用
收藏
页码：339A / 340A
页数：2
相关论文
共 50 条
  • [21] Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
    Larson, RA
    Sievers, EL
    Stadtmauer, EA
    Löwenberg, B
    Estey, EH
    Dombret, H
    Theobald, M
    Voliotis, D
    Bennett, JM
    Richie, M
    Leopold, LH
    Berger, MS
    Sherman, ML
    Loken, MR
    van Dongen, JJM
    Bernstein, ID
    Appelbaum, FR
    CANCER, 2005, 104 (07) : 1442 - 1452
  • [22] EFFICACY AND SAFETY OF GEMTUZUMAB OZOGAMICIN, FLUDARABINE, ARA-C, AND CYCLOSPORINE A (MFAC) AS POST-REMISSION THERAPY IN ELDERLY AML PATIENTS
    Caramazza, D.
    Siragusa, S.
    Palazzolo, R.
    Maisano, S.
    Abbene, I.
    Piazza, G.
    Quintini, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 533 - 534
  • [23] Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)
    Bixby, Dale L.
    Stein, Anthony S.
    Fathi, Amir T.
    Kovacsovics, Tibor J.
    Levy, Moshe Y.
    Erba, Harry P.
    Lancet, Jeffrey E.
    Jillella, Anand P.
    Ravandi, Farhad
    Walter, Roland B.
    Stein, Eytan M.
    Faderl, Stefan
    DeAngelo, Daniel J.
    Ho, Phoenix
    O'Meara, Megan M.
    Voellinger, Jenna L.
    Advani, Anjali
    BLOOD, 2016, 128 (22)
  • [24] Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML)
    Stein, Eytan M.
    Stein, Anthony
    Walter, Roland B.
    Fathi, Amir T.
    Lancet, Jeffrey E.
    Kovacsovics, Tibor J.
    Advani, Anjali S.
    DeAngelo, Daniel J.
    O'Meara, Megan M.
    Zhao, Baiteng
    Kennedy, Dana A.
    Erba, Harry P.
    BLOOD, 2014, 124 (21)
  • [25] Gemtuzumab ozogamicin, fludarabine, ara-C and cyclosporineA (MFAC) regimen as induction therapy in relapsed or refractory CD33+acute myeloid leukaemia prior to allogeneic haematopoetic stem cell transplantation: a single-centre experience
    von Bonin, M.
    Oelschlaegel, U.
    Mohr, B.
    Platzbecker, U.
    Thiede, C.
    Bornhaeuser, M.
    Ehninger, G.
    Illmer, T.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S95 - S96
  • [26] A Phase Ib Dose-Finding Study of Oral Panobinostat In Combination with Cytarabine (ara-C) and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia (AML)
    Krauter, Jurgen
    Schlenk, Richard F.
    Schaich, Markus
    Bouscary, Didier
    Dombret, Herve
    Winiger, Ivo J.
    Squier, Margaret
    Bengoudifa, Bourras-Rezki
    Ottmann, Oliver G.
    BLOOD, 2010, 116 (21) : 1356 - 1356
  • [27] PHASE 1B RESULTS OF IDASANUTLIN plus CYTARABINE (ARA-C) IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS (PTS)
    Martinelli, G.
    Pappayannidis, C.
    Yee, K.
    Vey, N.
    Drummond, M.
    Kelly, K.
    Dickinson, M.
    Lee, J. H.
    Seiter, K.
    Yoon, S. S.
    Assouline, S.
    Kasner, M.
    Nichols, G.
    Middleton, S.
    Blotner, S.
    Zhi, J.
    Pierceall, W.
    Chen, L. C.
    HAEMATOLOGICA, 2016, 101 : 187 - 187
  • [28] PHASE 1B RESULTS OF IDASANUTLIN plus CYTARABINE (ARA-C) IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS (PTS)
    Martinelli, G.
    Papayannidis, C.
    Paolini, S.
    Yee, K.
    Vey, N.
    Drummond, M.
    Kelly, K.
    Dickinson, M.
    Lee, J. Hwan
    Seiter, K.
    Yoon, S. Soo
    Assouline, S.
    Kasner, M.
    Nichols, G.
    Middleton, S.
    Blotner, S.
    Zhi, J.
    Pierceall, W.
    Chen, L. C.
    HAEMATOLOGICA, 2017, 102 : 48 - 48
  • [29] A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F-ara-A) and cytarabine (ara-C) for refractory or recurrent pediatric acute myeloid leukemia (AML)
    Leahey, A
    Kelly, K
    Rorke, LB
    Lange, B
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1997, 19 (04) : 304 - 308
  • [30] A phase Ib study of oral panobinostat (LBH589) in combination with cytarabine (ARA-C) and mitoxantrone (MT) as salvage therapy for refractory or relapsed acute myeloid leukemia (AML)
    Krauter, J.
    Ottmann, O. G.
    Schlenk, R. F.
    Schaich, M.
    Bouscary, D.
    Dombret, H.
    Luedicke, F.
    Weber, H. J.
    Winiger, I. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345